Jaap JanBoelensMDPhD(He/Him)

Pediatric Hematology & Oncology • New York, NY

Chief, Transplantation and Cellular Therapies

Overview of Dr. Boelens

Dr. Jaap Jan Boelens is a pediatric-oncologist in New York, NY at Memorial Sloan Kettering Cancer Center and New York-Presbyterian Hospital. He is Prof of Pediatrics at WCMC. He has experience in transplantation (and gene-therapy) for sickle cell disease, lysosomal storage diseases and refractory leukemias. Research: PKPD and immune reconstitution and has 300+ publications and 17K+ citations!

Office
1275 York Avenue
New York, NY 10065
Book by Phone+1(712) 628-6486

Education & Training

Utrecht University Faculty of MedicineClass of 1996

Certifications & Licensure

FL State Medical License 2022 - Present
NY State Medical License 2019 - 2025

Clinical Trials

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies Start of enrollment: 2021 Dec 01
Recruiting
Phase 1, Phase 2
Roles: Contact
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders Start of enrollment: 2020 Nov 20
Recruiting
Phase 2
Roles: Contact
Conditioning SCID Infants Diagnosed Early Start of enrollment: 2018 Oct 22
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT Start of enrollment: 2022 Mar 31
Recruiting
Phase 1, Phase 2
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) Start of enrollment: 2023 Feb 09
Recruiting
Phase 2
Roles: Contact
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML Start of enrollment: 2022 Oct 06
Recruiting
Phase 1, Phase 2
Roles: Contact
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition Start of enrollment: 2023 Mar 15
Recruiting
Phase 2
A Study of Emapalumab for Pediatric Aplastic Anemia Start of enrollment: 2024 May 21
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
The role of the conditioning regimen for autologous and ex vivo genetically modified hematopoietic stem cell-based therapies: recommendations from the ISCT stem cell e...
Joseph H Oved, Athena Russell, Amy DeZern, Susan E Prockop, Carmem Bonfim
Cytotherapy. 2025-01-01
Successful hematopoietic cell transplantation utilizing myeloablative reduced-toxicity conditioning in Chediak-Higashi syndrome.
Alan Bidgoli, Binni Kunvarjee, Andromachi Scaradavou, Richard J O'Reilly, Jaap Jan Boelens
The Journal of Allergy and Clinical Immunology. 2024-12-16
Model-based dosing for better survival after transplantation.
Jaap Jan Boelens, Michael Scordo
Blood Advances. 2024-12-10

Abstracts/Posters

Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL
Jaap Jan Boelens, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019